Ticagrelor Tablet, Film Coated
Product Images NDC 67877-522

Product Visual Gallery

This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 67877-522). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ascend Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ticagrelor-14s-count001-b (Ticagrelor 14s Count001 B)

The label for Ticagrelor Tablets 60 mg film-coated tablets from Ascend Laboratories, LLC. The label indicates 14 tablets per package, Rx only, with storage instructions and warnings. It lists manufacturer Alkem Laboratories Ltd. in Mumbai, India, and distributor Ascend Laboratories, LLC in Bedminster, NJ. Includes a barcode and lot code area.*

FDA Label Image

Ticagrelor 500 Label (Ticagrelor 500 3b)

Label for Ticagrelor Tablets 60 mg, film-coated oral tablets. The label states it contains 60 mg of ticagrelor per tablet, with a quantity of 500 tablets per container. It is manufactured by Alkem Laboratories Ltd., Mumbai, India and distributed by Ascend Laboratories, LLC, Bedminster, NJ. The label includes dosage instructions, warnings, and a barcode.*

FDA Label Image

Ticagrelor-deboss (Ticagrelor Deboss)

Ticagrelor 60 mg film-coated tablet, oral dosage form. The image shows a single round, white film-coated tablet marked with the imprint "A9" on one side. Labeled by Ascend Laboratories, LLC.*

FDA Label Image

Ticagrelor-fig1 (Ticagrelor Fig1)

A line graph comparing the cumulative percentage of events over 360 days from the first study drug dose between Ticagrelor 90 mg and Clopidogrel. The x-axis shows days from first dose, and the y-axis shows cumulative percentage. Two lines represent patients treated with Ticagrelor and Clopidogrel, with Ticagrelor showing a higher cumulative percentage over time. Patient numbers at risk are listed below the x-axis.*

FDA Label Image

Ticagrelor-fig10 (Ticagrelor Fig10)

Kaplan-Meier curve showing cumulative percentage of events over days from randomization comparing Ticagrelor 90 mg and Clopidogrel. The chart includes patient numbers and statistics such as hazard ratio (HR), confidence interval (CI), and p-value, illustrating event rates and risk comparison between the two treatments over 360 days.*

FDA Label Image

Ticagrelor-fig11 (Ticagrelor Fig11)

A forest plot chart comparing the hazard ratios (HR) with 95% confidence intervals between Ticagrelor and Clopidogrel across various patient characteristics and subgroups. The graph visually presents treatment effects with points and horizontal lines plotted against a central vertical line indicating no difference, showing multiple categories including geographic region, ASA dose, age, sex, race, and clinical conditions.*

FDA Label Image

Ticagrelor-fig12 (Ticagrelor Fig12)

A data table and accompanying forest plot figure showing hazard ratios (HR) with 95% confidence intervals comparing Ticagrelor versus Clopidogrel, broken down by aspirin (ASA) dose ranges and geographic regions (US and Non-US). The table includes subject counts and event numbers for each group and dose level.*

FDA Label Image

Ticagrelor-fig13 (Ticagrelor Fig13)

A cumulative percentage line graph showing outcomes over time (days from randomization) for Ticagrelor at 60 mg and 90 mg doses compared to placebo. The x-axis represents days up to approximately 1320, and the y-axis represents cumulative percentage events up to 11%. A table below the graph details the number of patients at risk over time for each group.*

FDA Label Image

Ticagrelor-fig14 (Ticagrelor Fig14)

A forest plot comparing hazard ratios (HR) and 95% confidence intervals (CI) for the treatment effects of Ticagrelor versus placebo across various patient characteristics, including age, sex, race, weight, BMI, geographic region, history of myocardial infarction, type of qualifying MI, diabetes status, multivessel coronary artery disease, creatinine clearance, PCI history, stent type, smoking status, and time since previous ADP receptor blocker treatment.*

FDA Label Image

Ticagrelor-fig15 (Ticagrelor Fig15)

A Kaplan-Meier cumulative percentage plot showing event rates for Ticagrelor versus Placebo over 54 months from randomization. The solid line represents Ticagrelor and the dashed line represents Placebo. Below the x-axis is the number of patients at risk at various time points for both groups.*

FDA Label Image

Ticagrelor-fig16 (Ticagrelor Fig16)

This figure is a forest plot displaying hazard ratios (HR) with 95% confidence intervals for various patient characteristics comparing Ticagrelor to placebo. It includes subgroups based on age, sex, race, body mass index, geographic region, baseline aspirin dose, HbA1c, renal function, insulin use, medical history, smoking status, and diabetes duration. The horizontal axis indicates treatment effect, with values less than 1 favoring Ticagrelor and greater than 1 favoring placebo.*

FDA Label Image

Ticagrelor-fig17 (Ticagrelor Fig17)

A Kaplan-Meier cumulative percentage curve comparing Ticagrelor 90 mg twice daily and placebo over approximately 34 days from randomization. The graph plots cumulative % events against days, with data tables showing numbers at risk for each group over time.*

FDA Label Image

Ticagrelor-fig18 (Ticagrelor Fig18)

A forest plot chart illustrating hazard ratios (HR) with 95% confidence intervals (CI) comparing Ticagrelor 60 mg to placebo across various patient subgroups and characteristics. The chart includes data points such as age, sex, race, region, diagnosis status, baseline medication use, and clinical history factors, showing relative risk outcomes for Ticagrelor versus placebo.*

FDA Label Image

Ticagrelor-fig2 (Ticagrelor Fig2)

A bar graph comparing the percentage of patients who had an event following CABG over several days (1 to 8 or more) between two groups labeled T and C. The vertical axis represents the percentage of patients, and the horizontal axis represents the days. Data counts are provided below the bars for each group at each time interval.*

FDA Label Image

Ticagrelor-fig3-a (Ticagrelor Fig3 A)

A line graph depicting cumulative percentage of events over months from randomization for Ticagrelor and placebo groups. The solid line represents Ticagrelor, showing a higher cumulative percentage than the dashed line for placebo. The x-axis indicates months up to 54 and the y-axis shows cumulative percentage from 0% to 7%. Below the graph, numbers at risk for both groups are provided for various time points.*

FDA Label Image

Ticagrelor-fig4 (Ticagrelor Fig4)

A Kaplan-Meier cumulative percentage curve chart comparing Ticagrelor 90 mg twice daily versus placebo over approximately 34 days. The chart shows cumulative events on the Y-axis and days from randomization on the X-axis, with Ticagrelor represented by a solid line and placebo by a dashed line. A risk table is included below the graph showing numbers at risk over time.*

FDA Label Image

Ticagrelor-fig5 (Ticagrelor Fig5)

A line graph comparing the IPA (%) induced by 20μM ADP over time (hours) for Ticagrelor 180 mg, Clopidogrel 600 mg, and placebo. The graph shows Ticagrelor achieving the highest IPA, followed by Clopidogrel and placebo, with values plotted up to 8 hours.*

FDA Label Image

Ticagrelor-fig6 (Ticagrelor Fig6)

A line graph showing IPA (%) induced by 20 micromolar ADP over time (days) comparing Ticagrelor, Clopidogrel, and Placebo groups. The graph depicts data points with Ticagrelor (circles) and Clopidogrel (triangles) showing higher IPA percentages that decrease over time, while Placebo (squares) remains low throughout. An inset graph displays IPA (%) over time (hours) for the same groups with a similar trend.*

FDA Label Image

Ticagrelor-fig7 (Ticagrelor Fig7)

A clinical pharmacokinetic chart titled 'Mean effect and 90% CI' for Ticagrelor shows intrinsic factors such as age, gender, ethnicity, renal impairment, end-stage renal disease on hemodialysis, and mild hepatic impairment. The chart includes two sets of data points labeled Ticagrelor and AR-C124910XX, representing Cmax and AUC with error bars, depicting changes relative to a reference baseline. Recommendations indicate no dose adjustment for all factors.*

FDA Label Image

Ticagrelor-fig8 (Ticagrelor Fig8)

A pharmacokinetic chart displaying the mean effect and 90% confidence intervals of various interacting drugs on Ticagrelor and AR-C124910XX. It includes changes in Cmax and AUC relative to reference for inhibitors and inducers such as ketoconazole, diltiazem, rifampin, aspirin, desmopressin, heparin, enoxaparin, cyclosporine, morphine, and fentanyl, along with dosing recommendations or adjustments.*

FDA Label Image

Ticagrelor-fig9 (Ticagrelor Fig9)

A chart showing the mean effect and 90% confidence interval of various interacting drugs on Ticagrelor pharmacokinetics, with changes relative to the interacting drug alone on the x-axis. It compares Cmax and AUC values for drugs like Simvastatin, Atorvastatin, Levonorgestrel, Ethinyl Estradiol, Tolbutamide, Digoxin, and Cyclosporine, with dosage adjustment recommendations noted in a right-hand column.*

FDA Label Image

Ticagrelor-struct (Ticagrelor Struct)

Chemical structure of ticagrelor depicted as a 2D molecular diagram showing its atoms and bonds, including functional groups with fluorine and hydroxyl components.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.